Skip to main content

Adding darolutamide to standard treatment may lower risk of spread of prostate cancer

Interim results of a large clinical trial show promise of darolutamide for patients with prostate cancer at high risk of metastasis or recurrence.
11/16/2026

Register for free access or login.

Canadian Healthcare Network is an independent online community for Canadian healthcare professionals in medicine and pharmacy. It is the online home of the Medical Post and Pharmacy Practice + Business.

Membership is free and allows doctors, pharmacists, nurses and many others to get the latest breaking news, updates on clinical guidelines and read (and even write) commentary from your healthcare peers.

X
This ad will auto-close in 10 seconds